HC Wainwright restated their buy rating on shares of Phathom Pharmaceuticals (NASDAQ:PHAT - Free Report) in a report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $28.00 price target on the stock.
Separately, Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Wednesday.
Read Our Latest Analysis on PHAT
Phathom Pharmaceuticals Trading Down 4.9 %
Shares of NASDAQ PHAT traded down $0.41 during mid-day trading on Thursday, hitting $7.99. The company had a trading volume of 992,436 shares, compared to its average volume of 914,171. The firm has a 50-day simple moving average of $13.29 and a two-hundred day simple moving average of $13.19. The company has a market capitalization of $546.33 million, a PE ratio of -1.48 and a beta of 0.56. Phathom Pharmaceuticals has a one year low of $6.07 and a one year high of $19.71.
Institutional Trading of Phathom Pharmaceuticals
Large investors have recently made changes to their positions in the company. Huntington National Bank raised its stake in Phathom Pharmaceuticals by 62.2% during the third quarter. Huntington National Bank now owns 1,471 shares of the company's stock worth $27,000 after acquiring an additional 564 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Phathom Pharmaceuticals by 41.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company's stock worth $43,000 after purchasing an additional 722 shares in the last quarter. US Bancorp DE lifted its stake in Phathom Pharmaceuticals by 28.6% in the 3rd quarter. US Bancorp DE now owns 5,248 shares of the company's stock valued at $95,000 after purchasing an additional 1,166 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Phathom Pharmaceuticals by 42.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,071 shares of the company's stock valued at $104,000 after buying an additional 2,987 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Phathom Pharmaceuticals by 10.6% during the second quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company's stock worth $144,000 after buying an additional 1,339 shares during the last quarter. Institutional investors and hedge funds own 99.01% of the company's stock.
About Phathom Pharmaceuticals
(
Get Free Report)
Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Featured Stories
Before you consider Phathom Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.
While Phathom Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
